NextCell Pharma: SEK15m directed issue and strategic update - Redeye
Redeye provides commentary on NextCell following the announcement of a SEK15m directed issue and a strategic update relating to its lead candidate ProTrans in type 1 diabetes. We adjust our valuation accordingly.
ANNONS
Redeye provides commentary on NextCell following the announcement of a SEK15m directed issue and a strategic update relating to its lead candidate ProTrans in type 1 diabetes. We adjust our valuation accordingly.